As expected, pERK1/2 was highly enriched in cell nuclei near the invasive edge of tumor samples where cells remained active and motile (Figure 4G), while counterparts from C:IRIS immunized primary tumors had significantly lower nuclear pERK1/2 (Figure 4G,J), suggesting that the inhibition of the ERK1/2 pathway in tumors from C:IRIS treated mice. The gene discussed is MAPK3; the disease is neoplasm.